Healthcare / Medical Instruments & SuppliesShanghai
$16.55
+0.16 (+0.98%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-185.8M · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
27/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$9.6B
P/E
63.7x
↑EV/EBITDA
16.7x
↑ROE
2.8%
↑Gross Margin
75.8%
↑Debt/Equity
0.16
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-36.6%
FCF CAGR
—
FCF margin
-11.3%
FCF / Net income
-0.93x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.64B · net income $198.9M · FCF $-185.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.64B | $1.64B | $1.46B | $1.01B | $6.45B |
| Net Income | $198.9M | $198.9M | $275.6M | $363.7M | $1.94B |
| EBITDA | $410.8M | $410.8M | $430.5M | $529.8M | $2.42B |
| EPS | 0.34 | 0.34 | 0.47 | 0.62 | 3.31 |
| Gross Margin | 75.8% | 75.8% | 77.9% | 71.5% | 58.8% |
| Operating Margin | 12.8% | 12.8% | 12.8% | 5.1% | 39.3% |
| Net Margin | 12.1% | 12.1% | 18.9% | 36.1% | 30.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.16 | 0.16 | 0.06 | 0.01 | 0.00 |
| Cash Flow | |||||
| Free Cash Flow | $-185.8M | $-185.8M | $-146.7M | $-347.8M | $2.00B |
| Returns | |||||
| ROE | 2.8% | 2.8% | 3.8% | 5.1% | 25.8% |
| Valuation | |||||
| P/E | 63.65 | 63.65 | 44.43 | 31.10 | 6.76 |
| EV/EBITDA | 16.66 | 16.66 | 18.76 | 13.43 | 4.10 |
| P/B | 1.36 | 1.36 | 1.69 | 1.57 | 1.75 |
| Growth & Yield | |||||
| Revenue Growth | 12.6% | 12.6% | 44.8% | -84.4% | — |
| EPS Growth | -27.7% | -27.7% | -24.2% | -81.3% | — |
| Dividend Yield | 3.1% | 3.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
62.9%
EPS terminal req.
$1.47
Spread vs growth
-90.5%
5Y implied EPS CAGR
39.2%
EPS terminal req.
$1.78
Spread vs growth
-66.9%
10Y implied EPS CAGR
23.7%
EPS terminal req.
$2.86
Spread vs growth
-51.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-14.1%
Start / end P/E
42.5x → 48.7x
EPS bridge
0.47 → 0.34
Residual
-4.0%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.